| Zhang, Jianzhong |
NCT06126965: Phase III Study of KX-826 With Adult Male Patients With AGA |
|
|
| Active, not recruiting | 3 | 740 | RoW | KX-826-（5%） BID, KX-826-5 mg(5%)60mL BID, Placebo | Suzhou Kintor Pharmaceutical Inc,, Suzhou Koshine Biomedica, Inc. | Androgenetic Alopecia | 05/24 | 05/24 | | |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT04839328: A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 3 | 306 | RoW | 60mg Hemay005, Hemay005 tablet, Placebo, placebo tablet | Tianjin Hemay Pharmaceutical Co., Ltd | Psoriasis | 10/22 | 07/23 | | |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT05051761: Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata |
|
|
| Active, not recruiting | 3 | 420 | RoW | Jaktinib, placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Alopecia Areata | 12/24 | 12/24 | | |
NCT05676242: A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 400 | RoW | Jaktinib Hydrochloride Tablet | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 12/24 | 12/24 | | |
NCT05667623: To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD |
|
|
| Recruiting | 3 | 270 | RoW | 1% OPA-15406 Ointment, 0% OPA-15406 Vehicle | Otsuka Beijing Research Institute | Atopic Dermatitis (AD) | 07/24 | 01/25 | | |
NCT06173284: Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 510 | RoW | 611, Matching placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 09/25 | 05/26 | | |
NCT06277245: A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. |
|
|
| Recruiting | 3 | 354 | RoW | LNK01001, Placebo | Lynk Pharmaceuticals Co., Ltd | Atopic Dermatitis | 09/25 | 11/25 | | |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
NCT06277765: Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis |
|
|
| Not yet recruiting | 3 | 180 | RoW | CM310, placebo | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 05/25 | 05/25 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
NCT05255237: Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata |
|
|
| Recruiting | 3 | 210 | RoW | Jaktinib | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Alopecia Areata | 06/24 | 12/24 | | |
NCT05526222: A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 438 | RoW | Jaktinib Hydrochloride Tablet | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 06/24 | 09/24 | | |
NCT05265923: A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis |
|
|
| Completed | 3 | 500 | RoW | CM310, Placebo | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 10/23 | 12/23 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06477835: A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 250 | NA | SIM0718 Injection | Simcere Pharmaceutical Co., Ltd | Atopic Dermatitis | 08/25 | 07/26 | | |
NCT06026891: Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis |
|
|
| Recruiting | 3 | 498 | RoW | MG-K10/Placebo | Shanghai Mabgeek Biotech.Co.Ltd | Atopic Dermatitis | 06/25 | 12/25 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT06477536: Long-Term Safety and Efficacy of HB0034 in Subjects with Generalized Pustular Psoriasis |
|
|
| Recruiting | 2/3 | 33 | RoW | HB0034, Anti-IL-36R antibody,Recombinant Humanized anti-IL-36R Monoclonal antibody | Shanghai Huaota Biopharmaceutical Co., Ltd. | Generalized Pustular Psoriasis | 12/25 | 06/26 | | |
NCT06554509: Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis |
|
|
| Recruiting | 2/3 | 236 | RoW | SHR-1819 injection, Placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | Prurigo Nodularis | 06/26 | 08/26 | | |
NCT06622824: To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia |
|
|
| Not yet recruiting | 2/3 | 756 | RoW | KX-826 0.5% BID, KX-826 1.0% BID, Vehicle (Placebo) applied BID | Suzhou Kintor Pharmaceutical Inc,, Suzhou Koshine Biomedica, Inc. | Androgenetic Alopecia (AGA) | 10/27 | 06/28 | | |
NCT05940506: Phase II Study Evaluating the Efficacy and Safety of KX-826 |
|
|
| Completed | 2 | 120 | RoW | KX-826-2.5 mg (0.25%)/60 mL BID, KX-826-2.5 mg (0.25%)/60 mL, KX-826-5 mg (5%)/60 mL QD, KX-826-5 mg (5%)/60 mL BID, Placebo | Suzhou Kintor Pharmaceutical Inc, | Androgenetic Alopecia (AGA) | 07/21 | 08/21 | | |
NCT04539639: Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis |
|
|
| Completed | 2 | 166 | RoW | Jaktinib, placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 05/22 | 05/22 | | |
NCT04893707: The Study of CM310 in Patients With Atopic Dermatitis |
|
|
| Completed | 2 | 127 | RoW | CM310, IL-4Rα monoclonal antibody | Keymed Biosciences Co.Ltd | Moderate-to-severe Atopic Dermatitis | 02/23 | 02/23 | | |
NCT05531682: A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 2 | 160 | RoW | Placebo, HB0017, HB0017 dosing regimens | Huabo Biopharm Co., Ltd. | Plaque Psoriasis | 05/23 | 01/24 | | |
NCT06085521: A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 2 | 150 | RoW | LNK01001 Dose A, LNK01001 Dose B, placebo | Lynk Pharmaceuticals Co., Ltd | Atopic Dermatitis | 06/23 | 06/23 | | |
| Completed | 2 | 93 | RoW | 611 Q2W, 611 Q4W, Matching placebo, placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 07/23 | 09/23 | | |
NCT05671432: The Study of CM326 in Moderate-to-severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 240 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Moderate-to-severe Atopic Dermatitis | 12/23 | 12/24 | | |
NCT06278350: Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 160 | RoW | D-2570, Placebo | InventisBio Co., Ltd | Plaque Psoriasis | 12/24 | 03/25 | | |
NCT06231381: Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP) |
|
|
| Recruiting | 2 | 33 | RoW | HB0034, Recombinant Humanized anti-IL-36R Monoclonal antibody, Placebo | Shanghai Huaota Biopharmaceutical Co., Ltd. | Generalized Pustular Psoriasis (GPP) | 08/25 | 11/25 | | |
NCT06118866: A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects with Androgenetic Alopecia |
|
|
| Recruiting | 2 | 180 | RoW | placebo-Q2W, HMI-115-120mg-Q4W, HMI-115-240mg-Q4W, HMI-115, 240mg-Q2W | Hope Medicine (Nanjing) Co., Ltd | Androgenetic Alopecia | 12/24 | 12/24 | | |
NCT05671445: The Study of CM326 in Adult Subjects With Atopic Dermatitis |
|
|
| Recruiting | 2 | 100 | RoW | CM326 | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 03/24 | 03/25 | | |
| Recruiting | 2 | 159 | Europe, Canada, Japan, US, RoW | GSK1070806 | GlaxoSmithKline | Dermatitis, Atopic | 11/29 | 11/29 | | |
NCT06509334: Trial of JYB1904 in Chronic Spontaneous Urticaria. |
|
|
| Not yet recruiting | 2 | 135 | RoW | JYB1904, Omalizumab | Jemincare | Chronic Spontaneous Urticaria | 07/26 | 07/26 | | |
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 175 | Europe, Canada, Japan, US, RoW | GSK1070806, Placebo | GlaxoSmithKline | Dermatitis, Atopic | 08/24 | 06/25 | | |
NCT05186922: The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis |
|
|
| Recruiting | 1/2 | 54 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Moderate-to-severe Atopic Dermatitis | 01/23 | 01/23 | | |
| Recruiting | 1/2 | 33 | RoW | Monoclonal antibody BAT6026, BAT6026, sodium chloride injection | Bio-Thera Solutions | Dermatitis, Atopic | 02/25 | 10/25 | | |
NCT06175143: A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis. |
|
|
| Not yet recruiting | 1 | 40 | RoW | GR2002 injection | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Atopic Dermatitis | 10/24 | 10/24 | | |
| Recruiting | N/A | 10000 | RoW | No intervention | Peking University People's Hospital | Dermatitis, Atopic | 10/24 | 10/24 | | |
